SBIO 股價展望與 ETF 分析 - 配息·管理費·持股·NAV·RSI·MACD | 美股今日

ALPS Medical Breakthroughs ETFSBIO | NYSE | 醫療類股 查看深度分析

ALPS Medical Breakthroughs ETF seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.